» Articles » PMID: 38201571

Diffusion-Weighted MRI As a Quantitative Imaging Biomarker in Colon Tumors

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Jan 11
PMID 38201571
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess the use of quantitative diffusion-weighted MRI (DW-MRI) as a diagnostic imaging biomarker in differentiating between benign colon adenoma, early, and advanced cancer of the colon, as well as predicting lymph node involvement, and finally comparing mucinous-producing colon cancer with adenomas and non-mucinous colon cancer.

Method: Patients with a confirmed tumor on colonoscopy were eligible for inclusion in this study. Using a 3.0 Tesla MRI machine, the main tumor mean apparent diffusion coefficient (mADC) was obtained. Surgically resected tumor specimens served as an endpoint, except in mucinous colon cancers, which were classified based on T2 images.

Results: A total of 152 patients were included in the study population. The mean age was 71 years. A statistically significant mADC mean difference of -282 × 10 mm/s [-419--144 95% CI, < 0.001] was found between colon adenomas and early colon cancer, with an AUC of 0.80 [0.68-0.93 95% CI] and an optimal cut off value of 1018 × 10 mm/s. Only a small statistically significant difference ( = 0.039) in mADC was found between benign tumors and mucinous colon cancer. We found no statistical difference in mADC mean values between early and advanced colon cancer, and between colon cancer with and without lymph node involvement.

Conclusion: Quantitative DW-MRI is potentially useful for determining whether a colonic tumor is benign or malignant. Mucinous colon cancer shows less diffusion restriction when compared to non-mucinous colon cancer, a potential pitfall.

Citing Articles

Impact of diffusion-weighted imaging on agreement between radiologists and non-radiologist in musculoskeletal tumor imaging using magnetic resonance.

Lodeiro G, Bokwa-Dabrowska K, Miron A, Szaro P Eur J Radiol Open. 2024; 13:100590.

PMID: 39104462 PMC: 11298833. DOI: 10.1016/j.ejro.2024.100590.

References
1.
Jia Y, Song G, Wu R, Hong Y, Dou W, Li A . Intravoxel incoherent motion DWI with different mathematical models in predicting rectal adenoma with and without canceration. Eur J Radiol. 2022; 155:110496. DOI: 10.1016/j.ejrad.2022.110496. View

2.
Garcia-Figueiras R, Baleato-Gonzalez S, Padhani A, Luna-Alcala A, Marhuenda A, Vilanova J . Advanced Imaging Techniques in Evaluation of Colorectal Cancer. Radiographics. 2018; 38(3):740-765. DOI: 10.1148/rg.2018170044. View

3.
Grosu S, Schafer A, Baumann T, Manegold P, Langer M, Gerstmair A . Differentiating locally recurrent rectal cancer from scar tissue: Value of diffusion-weighted MRI. Eur J Radiol. 2016; 85(7):1265-70. DOI: 10.1016/j.ejrad.2016.04.006. View

4.
Yue Y, Cheng M, Xi X, Wang Q, Wei M, Zheng B . Can neoadjuvant chemoradiotherapy combined with immunotherapy benefit patients with microsatellite stable locally advanced rectal cancer? a pooled and integration analysis. Front Oncol. 2023; 13:1280995. PMC: 10588447. DOI: 10.3389/fonc.2023.1280995. View

5.
Nerad E, Delli Pizzi A, Lambregts D, Maas M, Wadhwani S, Bakers F . The Apparent Diffusion Coefficient (ADC) is a useful biomarker in predicting metastatic colon cancer using the ADC-value of the primary tumor. PLoS One. 2019; 14(2):e0211830. PMC: 6363286. DOI: 10.1371/journal.pone.0211830. View